Radella reports positive outcomes from trial of MD-18 for obesity and diabetes

US-based biopharmaceutical company Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed the pharmacokinetics, safety and tolerability of MD-18, an investigational therapy for obesity and diabetes.